Efficacy and safety of policosanol in patients with primary hypercholesterolemia

摘要: Abstract A double-blind, placebo-controlled study was conducted in patients with primary hypercholesterolemia to examine the effects of policosanol on plasma lipids and lipoproteins. After adhering a cholesterol-lowering diet for 6 weeks, 56 were randomized receive placebo or 5 mg once daily evening 8 weeks. Total cholesterol low-density lipoprotein decreased significantly, by an average 13.1% 17.7%, respectively. No significant changes observed triglycerides, very-low-density cholesterol, high-density cholesterol. differences clinical biochemical safety indicators seen treated compared those receiving placebo. There no adverse attributable treatment, patient withdrawn from trial. These data indicate that therapy is effective very well tolerated.